Long-term outcomes and predictors of mortality in patients with pulmonary embolism undergoing catheter-directed thrombolysis: a 10-year retrospective study

Curr Probl Cardiol. 2024 May;49(5):102471. doi: 10.1016/j.cpcardiol.2024.102471. Epub 2024 Feb 16.

Abstract

Background: Data regarding long-term outcomes of catheter-directed thrombolysis (CDT) post intermediate risk pulmonary embolism (PE), the choice of anticoagulation, and factors affecting mortality are not well studied.

Methods: We conducted a ten-year retrospective observational chart review of patients undergoing CDT for intermediate-risk PE. Patients were followed for a period of 1 to a maximum of 5 years from the PE event. Multivariate regression analysis was used to identify independent predictors of mortality post-CDT.

Results: We had a total of 373 patients in our study. Significant 5-year mortality was observed (18.7 %) in our patient population, with a 9.2 % cardiopulmonary cause of death. Rate was highest in patients without anticoagulation (78.5 %) and least in patients on apixaban [10.9 %, absolute risk reduction - 63.8 % (40.91 % - 86.60 %)]. Age, female sex and no anticoagulation were independently associated with mortality.

Conclusion: CDT for intermediate-risk PE has a high 5-year mortality with no anticoagulation as the only modifiable risk factor.

Keywords: Anticoagulation; CDT; Catheter-directed thrombolysis; Intermediate-risk PE; Pulmonary embolism.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Catheters
  • Female
  • Fibrinolytic Agents* / therapeutic use
  • Humans
  • Male
  • Observational Studies as Topic
  • Pulmonary Embolism* / drug therapy
  • Retrospective Studies
  • Thrombolytic Therapy / adverse effects
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents